Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Individuals With ADHD

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Attention Deficit Hyperactivity Disorders
Interventions
DRUG

Psychostimulants

"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."

Trial Locations (1)

V6T 2A1

Developmental Cognitive Neuroscience Lab, Department of Psychiatry, University of British Columbia, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER

NCT02167048 - Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Individuals With ADHD | Biotech Hunter | Biotech Hunter